Modern Thyroid Clinic Health Directory

SLOT: Full Definition

What are GLP-1 agonists?

GLP-1 receptor agonists — also called GLP-1 RAs — are a class of medications that mimic glucagon-like peptide-1, a hormone the gut naturally releases after meals. They were originally developed for type 2 diabetes and have since transformed obesity care, with several products now FDA-approved specifically for chronic weight management. Common GLP-1 agonists include Liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound) — though tirzepatide technically activates both GLP-1 and GIP receptors.

At Modern Thyroid Clinic, GLP-1 agonists have become an important option for women dealing with insulin resistance, PCOS, perimenopausal weight gain, and stubborn metabolic dysfunction tied to thyroid disease.

How do GLP-1 agonists work?

GLP-1 agonists work in several places at once:

Brain: reduce appetite and quiet "food noise" — the persistent thoughts about food many women describe
Stomach: slow gastric emptying, increasing fullness after meals
Pancreas: stimulate insulin release in a glucose-dependent way
Liver: lower glucagon, reducing the liver's release of glucose between meals

The combined effect is steadier blood sugar, smaller portion sizes, and meaningful weight loss for most patients — often in the range of 10-20% of body weight depending on the specific agent and dose.

When are GLP-1 agonists prescribed?

GLP-1 agonists are commonly prescribed for:

Type 2 diabetes, often as a second-line agent after Metformin
Chronic weight management in adults with BMI ≥ 30, or BMI ≥ 27 plus a weight-related condition
Cardiovascular risk reduction in patients with diabetes and heart disease
Off-label and emerging uses: PCOS, fatty liver, and perimenopausal metabolic dysfunction

Patient considerations

The most common side effects are gastrointestinal — nausea, constipation, reflux, and occasional diarrhea — particularly during dose escalation. Most settle over time. All GLP-1 agonists carry a boxed warning regarding medullary thyroid cancer and MEN-2 syndrome and should not be used in patients with that personal or family history. Pancreatitis and gallbladder disease are rare but recognized risks.

Long-term use is generally expected — obesity and insulin resistance are chronic conditions. At MTC, we pair GLP-1 therapy with protein-forward nutrition, strength training, sleep work, and thyroid optimization, because the medication is most effective when it sits inside a foundation of metabolic health. Decisions about which GLP-1 agonist (if any) is right for you should always be made with a clinician who knows your full medical and hormonal picture.

Common symptoms

Common questions

Are GLP-1 agonists safe for the thyroid?

For most women, yes. The boxed warning on the GLP-1 class is based on rodent studies showing thyroid C-cell tumors at high doses; this has not been demonstrated in humans, but caution is appropriate. Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN-2) should not use these medications. For women with [hashimotos-thyroiditis] or hypothyroidism, GLP-1 agonists are generally safe — and often helpful — but [tsh] should be rechecked more frequently as weight changes can shift thyroid medication needs.

Which GLP-1 agonist is best?

There is no single "best" — the right choice depends on goals, tolerance, access, and budget. Tirzepatide (Zepbound, Mounjaro) tends to produce the greatest average weight loss because it activates two receptors. Semaglutide (Wegovy, Ozempic) is well-studied with strong outcome data. [liraglutide] (Saxenda, Victoza) is shorter-acting and dosed daily, which some patients prefer for side-effect control. At Modern Thyroid Clinic we match the medication to the patient: insulin resistance pattern, diabetes status, prior tolerance, and what insurance will actually cover.

Will I lose muscle on a GLP-1 agonist?

Possibly, if the medication is used without nutrition and training support. With any rapid weight loss — including from GLP-1 agonists — about 25-40% of the lost weight can be lean tissue if protein intake is low and there is no resistance training. This is especially risky for women in [perimenopause] and beyond, when muscle is harder to preserve. At MTC we strongly emphasize 1.0-1.2 grams of protein per pound of ideal body weight and progressive strength training while on these medications, so you lose fat — not function.

Think you might be dealing with this?

Talk to a Modern Thyroid Clinic specialist about your symptoms, labs, and next steps.

Book a Discovery Call

This content is for educational purposes only and is not medical advice. Consult a licensed clinician for diagnosis and treatment. Content on this page does not create a doctor-patient relationship with Modern Thyroid Clinic.